Limited therapeutic options exist for the treatment of vancomycin-resistant Enterococcus (VRE) bacteraemia; the most commonly used are daptomycin and linezolid. We attempted a systematic review and meta-analysis on the comparative efficacy of those two agents. Studies comparing daptomycin to linezolid treatment for VRE bacteraemia, published until August 2012 were identified from MEDLINE, EMBASE, CENTRAL, ISI Web of Science and SCOPUS databases. All comparative studies on patients older than 18 years old that provided mortality data were considered eligible for this systematic review and meta-analysis. Τhe primary outcome of the meta-analysis was 30-day all-cause mortality. Ten retrospective studies including 967 patients were identified. Patients treated with daptomycin had significantly higher 30-day all-cause mortality (OR: 1.61, 95% CI: 1.08 to 2.40) and infection-related mortality (OR: 3.61, 95% CI: 1.42 to 9.20) rates compared to those treated with linezolid. When data from all ten studies were combined overall mortality was also significantly increased among patients treated with daptomycin (OR: 1.41, 95% CI: 1.06 to 1.89). These findings were confirmed when odds ratios adjusted for potential confounders were pooled. Relapse rates among patients treated with daptomycin were also higher (OR: 2.51, 95% CI: 0.94 to 6.72), although this difference did not reach statistical significance. Adverse event rates were not significantly different between the two groups. Notwithstanding the absence of randomized prospective data, available evidence suggests that mortality rates may be higher with daptomycin compared with linezolid among patients treated for VRE bacteraemia. 
with either one of the two agents were not included.
98

Studies identified
99
The electronic search resulted in the retrieval of 2365 publications (see Fig. S1 included in this systematic review and meta-analysis (4, 5, (20) (21) (22) (23) (24) (25) (26) (27) .
115
Data extraction
116
The methodology that was followed for extracting the data is described in the 117 supplemental material.
118
Outcomes
119
The primary outcome examined in the meta-analysis was mortality, expressed as 30- 
137
Quantitative data synthesis
138
This is presented in detail in the supplemental material. 
Results
142
Systematic review
143
The ten studies identified as fulfilling the inclusion criteria for the systematic review studies the primary outcome among those examined was not stated.
152
The sample size of the included studies ranged from 31 to 201 patients (median 82).
153
With two exceptions (25, 26) , the studies included mixed populations with varying 154 percentages of immunocompromised and non-immunocompromised patients (see 155   Table S2 in the supplemental material).
156
Definitions of VRE BSIs differed slightly across studies. The Centers for Disease supplemental material. Adjustments for potential confounders by the authors were 166 performed using multivariable logistic regression analysis in six studies (4, 20-22, 24, 167 27).
168
The median daily daptomycin dose was 6mg/kg in six studies (5, 20-22, 26, 27), 169 5.5mg/kg in one study (25), and dose was not reported in three studies (4, 23, 24 and between 11 and 15 days in the linezolid group, respectively (20) (21) (22) 27 ).
172
Combination with aminoglycosides was reported in two studies (21, 27 Table S4 in the supplemental material).
175
Prior vancomycin use was reported in two studies (21, 27), being significantly Figure 4A ).
Meta-analysis
237
Six studies offered data on this outcome (5, 20, 22, 23, 26, 27) . when data from individual studies were combined (see Table S5 in the supplemental 249 material). of patients included, other antibiotics used, doses, etc., summarized in Tables S2-S4). effects model, and the pooled estimates for all mortality outcomes remained unaltered
277
(data not shown). Hence, the results obtained in this meta-analysis are stable and, 278 thus, they seem to accurately reflect the underlying effect present in the available 279 comparative studies.
280
In order to further increase the statistical power of this meta-analysis, a composite 281 outcome of overall mortality rate was calculated. This outcome combined data on 25-27); and combination therapies were not available for all patients (21, 27).
298
Although such biases cannot be eliminated outside the context of a randomized 299 prospective trial, we note that results from adjustment that took into account known 300 confounders (listed in 
